CLDI Receives NYSE American Delisting Notice for Stockholders' Equity Deficiency
Calidi Biotherapeutics received a non-compliance notice from NYSE American on September 21, 2026, for failing to maintain the required $4.0 million minimum stockholders' equity while reporting losses in three of four recent fiscal years and not qualifying for available exemptions.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
NYSE American notified CLDI that it violated continued listing standard Part 10, Section 1003(a)(ii), which requires minimum stockholders' equity of $4.0 million for companies with three-of-four-year loss history. The company is ineligible for exemptions, including the $50 million market capitalization exemption.
Why it matters
Stockholders' equity deficiency combined with ineligibility for exemptions creates material delisting risk. This signals deteriorating financial condition and inability to meet exchange standards, typically preceding formal delisting proceedings if not remedied within the cure period (typically 6 months).
Market transmission
Delisting risk reduces liquidity and increases cost of capital; equity holders face potential forced liquidation or restructuring; debt holders face heightened default risk; institutional investors may be forced to exit positions due to listing requirements.
What to watch
Announcement of equity raise, debt restructuring, or asset sale within cure period; formal delisting notice if no remediation plan accepted; stock price action and trading volume; any reverse split or recapitalization attempt; quarterly equity position updates.
Source:GlobeNewswire US
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.